Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Enhancer of Zeste Homolog 2 (EZH2) is a histone methyltransferase that silences gene expression and is a validated anticancer target.
• Current EZH2 inhibitors have limitations in treating solid tumors, necessitating novel therapeutic strategies.
• Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge.

Purpose of the Study:

• To identify novel therapeutic strategies for HNSCC by investigating the effects of EZH2 inhibition.
• To explore the molecular mechanisms underlying HNSCC response to EZH2 inhibitors.
• To discover combination therapies that enhance the efficacy of EZH2 inhibitors in HNSCC.

Main Methods:

• Genomics, metabolomics, and RNA omics studies were conducted on HNSCC cells treated with EZH2 inhibitors.
• Extensive drug screening was performed to identify compounds that synergize with EZH2 inhibitors.
• Analysis of gene expression related to cholesterol synthesis pathways was performed.

Main Results:

• EZH2 inhibitors significantly upregulated genes involved in cholesterol synthesis in HNSCC cells.
• Inhibition of squalene epoxidase, a key enzyme in cholesterol synthesis, increased squalene levels.
• Combined inhibition of EZH2 and squalene epoxidase synergistically enhanced the sensitivity of HNSCC cells to EZH2 inhibitors.

Conclusions:

• EZH2 inhibition induces cholesterol synthesis pathways in HNSCC.
• Targeting squalene epoxidase in combination with EZH2 inhibitors represents a promising therapeutic strategy for HNSCC.
• These findings provide a basis for developing novel combination therapies against HNSCC.